BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38752748)

  • 1. Enhancing probiotic impact: engineering
    de Carvalho BT; Subotić A; Vandecruys P; Deleu S; Vermeire S; Thevelein JM
    Appl Environ Microbiol; 2024 Jun; 90(6):e0032524. PubMed ID: 38752748
    [No Abstract]   [Full Text] [Related]  

  • 2. Unique genetic basis of the distinct antibiotic potency of high acetic acid production in the probiotic yeast
    Offei B; Vandecruys P; De Graeve S; Foulquié-Moreno MR; Thevelein JM
    Genome Res; 2019 Sep; 29(9):1478-1494. PubMed ID: 31467028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New biomarkers underlying acetic acid tolerance in the probiotic yeast Saccharomyces cerevisiae var. boulardii.
    Samakkarn W; Vandecruys P; Moreno MRF; Thevelein J; Ratanakhanokchai K; Soontorngun N
    Appl Microbiol Biotechnol; 2024 Jan; 108(1):153. PubMed ID: 38240846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Mutation in
    Liu JJ; Zhang GC; Kong II; Yun EJ; Zheng JQ; Kweon DH; Jin YS
    Appl Environ Microbiol; 2018 May; 84(10):. PubMed ID: 29523547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yeasts as probiotics: Mechanisms, outcomes, and future potential.
    Sen S; Mansell TJ
    Fungal Genet Biol; 2020 Apr; 137():103333. PubMed ID: 31923554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microbiome Engineering Using Probiotic Yeast:
    Kim J; Atkinson C; Miller MJ; Kim KH; Jin YS
    Microbiol Spectr; 2023 Aug; 11(4):e0078023. PubMed ID: 37436157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production of neoagarooligosaccharides by probiotic yeast Saccharomyces cerevisiae var. boulardii engineered as a microbial cell factory.
    Jin Y; Yu S; Liu JJ; Yun EJ; Lee JW; Jin YS; Kim KH
    Microb Cell Fact; 2021 Aug; 20(1):160. PubMed ID: 34407819
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Durmusoglu D; Al'Abri IS; Collins SP; Cheng J; Eroglu A; Beisel CL; Crook N
    ACS Synth Biol; 2021 May; 10(5):1039-1052. PubMed ID: 33843197
    [No Abstract]   [Full Text] [Related]  

  • 9. Improving therapeutic protein secretion in the probiotic yeast Saccharomyces boulardii using a multifactorial engineering approach.
    Durmusoglu D; Al'Abri I; Li Z; Islam Williams T; Collins LB; Martínez JL; Crook N
    Microb Cell Fact; 2023 Jun; 22(1):109. PubMed ID: 37287064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programming Probiotics: Diet-Responsive Gene Expression and Colonization Control in Engineered
    Durmusoglu D; Haller DJ; Al'Abri IS; Day K; Sands C; Clark A; San-Miguel A; Vazquez-Uribe R; Sommer MOA; Crook NC
    ACS Synth Biol; 2024 Jun; 13(6):1851-1865. PubMed ID: 38787439
    [No Abstract]   [Full Text] [Related]  

  • 11. Heterologous Expression of the Leuconostoc Bacteriocin Leucocin C in Probiotic Yeast Saccharomyces boulardii.
    Li R; Wan X; Takala TM; Saris PEJ
    Probiotics Antimicrob Proteins; 2021 Feb; 13(1):229-237. PubMed ID: 32567021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel insights in genetic transformation of the probiotic yeast Saccharomyces boulardii.
    Douradinha B; Reis VC; Rogers MB; Torres FA; Evans JD; Marques ET
    Bioengineered; 2014; 5(1):21-9. PubMed ID: 24013355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases.
    Kaźmierczak-Siedlecka K; Ruszkowski J; Fic M; Folwarski M; Makarewicz W
    Curr Microbiol; 2020 Sep; 77(9):1987-1996. PubMed ID: 32472262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Saccharomyces cerevisiae var. boulardii in co-fermentations with S. cerevisiae for the production of craft beers with potential healthy value-added.
    Capece A; Romaniello R; Pietrafesa A; Siesto G; Pietrafesa R; Zambuto M; Romano P
    Int J Food Microbiol; 2018 Nov; 284():22-30. PubMed ID: 29990636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strain engineering and metabolic flux analysis of a probiotic yeast Saccharomyces boulardii for metabolizing L-fucose, a mammalian mucin component.
    Kim J; Cheong YE; Yu S; Jin YS; Kim KH
    Microb Cell Fact; 2022 Oct; 21(1):204. PubMed ID: 36207743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete genome sequence and comparative genomics of the probiotic yeast Saccharomyces boulardii.
    Khatri I; Tomar R; Ganesan K; Prasad GS; Subramanian S
    Sci Rep; 2017 Mar; 7(1):371. PubMed ID: 28336969
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Pais P; Almeida V; Yılmaz M; Teixeira MC
    J Fungi (Basel); 2020 Jun; 6(2):. PubMed ID: 32512834
    [No Abstract]   [Full Text] [Related]  

  • 18. Growth, survival, and metabolic activities of probiotics Lactobacillus rhamnosus GG and Saccharomyces cerevisiae var. boulardii CNCM-I745 in fermented coffee brews.
    Chan MZA; Toh M; Liu SQ
    Int J Food Microbiol; 2021 Jul; 350():109229. PubMed ID: 34023682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional heterologous protein expression by genetically engineered probiotic yeast Saccharomyces boulardii.
    Hudson LE; Fasken MB; McDermott CD; McBride SM; Kuiper EG; Guiliano DB; Corbett AH; Lamb TJ
    PLoS One; 2014; 9(11):e112660. PubMed ID: 25391025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice.
    Everard A; Matamoros S; Geurts L; Delzenne NM; Cani PD
    mBio; 2014 Jun; 5(3):e01011-14. PubMed ID: 24917595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.